Molecular and Cellular Insights Into Retinoblastoma: Pathways, Immune Landscape, and Therapeutic Opportunities
Journal of Clinical Pharmacy and Therapeutics · 2025-01 · 2025 (1)
DOI: 10.1155/jcpt/7499930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 22.07.2025. Verfasst von Yixu Wang und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Retinoblastoma (RB) is the most common primary intraocular malignancy in children, primarily caused by inactivation of the RB1 tumor suppressor gene. Despite advancements in multimodal therapies, the molecular mechanisms underlying RB progression and its tumor microenvironment (TME) remain poorly understood, limiting the development of effective targeted treatments.
Methods
This study integrates bulk and single‐cell RNA sequencing data to characterize the molecular landscape of RB. Differential gene expression analysis, pathway enrichment analysis, and single‐sample gene set enrichment analysis (ssGSEA) were performed to uncover key pathways and immune cell populations. Immune checkpoint molecules, m6A RNA modification‐related genes, and ferroptosis‐associated genes were analyzed to identify potential therapeutic targets. Protein‐protein interaction (PPI) networks and cell‐cell communication analyses were conducted to explore intercellular signaling within the TME. Additionally, functional validation was performed for CDKN1A, a candidate gene identified from transcriptomic analysis, using shRNA‐mediated knockdown and in vitro assays.
Results
Transcriptomic profiling revealed distinct gene expression signatures between RB and normal retinal tissues, including upregulation of oncogenic pathways (e.g., MYC targets and G2/M checkpoint regulation) and downregulation of tumor suppressor pathways (e.g., p53 signaling). Chemotherapy‐induced gene expression changes were observed, notably the activation of immune‐related pathways such as antigen presentation and NK cell‐mediated cytotoxicity. Immune checkpoint molecules (PDCD1, CD274, HAVCR2) exhibited cell‐type‐specific expression, indicating potential for immunotherapy. Elevated expression of m6A regulators (METTL3, WTAP) and ferroptosis‐associated genes (ACSL4, SLC7A11) pointed to novel therapeutic vulnerabilities. Among key regulatory genes, CDKN1A was identified as significantly downregulated in RB. Functional experiments demonstrated that knockdown of CDKN1A inhibited cell proliferation and induced G1 phase arrest in RB cell lines, supporting its potential tumor‐promoting role in this context.
Conclusion
This study provides a comprehensive molecular and cellular overview of RB progression and reveals novel therapeutic targets, including immune checkpoints, m6A modification enzymes, ferroptosis regulators, and CDKN1A. Our findings emphasize the need to address tumor heterogeneity and cell‐type‐specific gene expression in designing effective personalized therapies for RB patients.
Zitieren
APA
Wang, Y., Quan, Y., Zhou, S., Dang, Y., Zhang, X., & Pei, C. (2025). Molecular and Cellular Insights Into Retinoblastoma: Pathways, Immune Landscape, and Therapeutic Opportunities. Journal of Clinical Pharmacy and Therapeutics, 2025(1). https://doi.org/10.1155/jcpt/7499930
Vancouver
Wang Y, Quan Y, Zhou S, Dang Y, Zhang X, Pei C. Molecular and Cellular Insights Into Retinoblastoma: Pathways, Immune Landscape, and Therapeutic Opportunities. Journal of Clinical Pharmacy and Therapeutics. 2025;2025(1). doi:10.1155/jcpt/7499930
BibTeX
@article{Wang2025,
author = {Wang, Yixu and Quan, Yumeng and Zhou, Shuyan and Dang, Yufei and Zhang, Xiaoxia and Pei, Cheng},
title = {Molecular and Cellular Insights Into Retinoblastoma: Pathways, Immune Landscape, and Therapeutic Opportunities},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/jcpt/7499930}
}
EUVIMED